ArticleMetallomics : integrated biometal science2026
SLC30A1, SLC30A5, and SLC30A9 transporters play crucial role in ligand-independent activation of ESR1 signalling in breast cancer cells via modulation of AKT activity by zinc.
Article in Metallomics : integrated biometal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc is essential for cellular homeostasis and acts both as a structural element and a secondary messenger in intracellular signalling. While the role of SLC39 (former ZIP) family transporters in breast cancer biology is intensively studied, the signalling function of SLC30 family transporters (former ZnT) remains insufficiently explored. This study investigates the involvement of SLC30 transporters in oestrogen receptor-positive (ER+) breast cancer. Bioinformatic and experimental analyses revealed that SLC30 transporters, particularly SLC30A1, SLC30A5, and SLC30A9, regulate the PTP/AKT/ESR1 pathway, contributing to hormone-independent ESR1 activation. Zn-dependent inhibition of PTP phosphatases modulates kinase signalling, promoting proliferation. Notably, high SLC30 expression correlates with improved survival, but serves as a negative prognostic marker under tamoxifen treatment. Here, we evidence that ESR1 directly represses SLC30 transcription and that zinc transporters form a regulatory feedback loop sustaining ER+ breast tumour progression. These findings position SLC30 transporters as active participants in signalling cascades, offering novel targets for therapeutic intervention in ER+ breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.